Arecoline inhibits epithelial cell viability by upregulating the apoptosis pathway: Implication for oral submucous fibrosis

Oncology Reports

Volumn 31, Issue 5, 2014, Pages 2422-2428

  Li, Ming ^a,b   Gao, Feng ^c,d   Zhou, Zhong Su ^b   Zhang, Hui Ming ^b   Zhang, Rui ^b   Wu, Ying Fang ^a   Bai, Ming Hai ^b   Li, Ji Jia ^a   Lin, Shi Rong ^e   Peng, Jie Ying ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Changsha Stomatology Hospital   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^e Taiwan Taipei Dental Sciences ^*  (Taiwan)

Author keywords

Apoptosis; Arecoline; Bid; Caspase 3; Oral submucous fibrosis

Indexed keywords

ARECOLINE; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BID; BID PROTEIN, HUMAN; CHOLINERGIC RECEPTOR STIMULATING AGENT;

APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MOUTH DISEASE; MTS ASSAY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ARECA; CELL LINE; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; FEEDING BEHAVIOR; KERATINOCYTE; METABOLISM; MOUTH MUCOSA; PATHOLOGY;

APOPTOSIS; ARECA; ARECOLINE; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 3; CELL LINE; CELL PROLIFERATION; CHOLINERGIC AGONISTS; EPITHELIAL CELLS; FIBROBLASTS; FOOD HABITS; HUMANS; KERATINOCYTES; MOUTH MUCOSA; ORAL SUBMUCOUS FIBROSIS;

EID: 84898662222     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3091     Document Type: Article

References (49)

1. Khan S, Chatra L, Prashanth SK, et al: Pathogenesis of oral submucous fibrosis. J Cancer Res Ther 8: 199-203, 2012
2. Arakeri G and Brennan PA: Oral submucous fibrosis: An overview of the aetiology, pathogenesis, classification, and principles of management. Br J Oral Maxillofacial Surg 51: 587-593, 2013
3. Cox SC and Walker DM: Oral submucous fibrosis. A review. Aust Dent J 41: 294-299, 1996
4. Mahomed F: Oral submucous fibrosis - a potentially malignant condition of growing concern. SADJ 67: 562-565, 2012
5. Chole RH, Gondivkar SM, Gadbail AR, et al: Review of drug treatment of oral submucous fibrosis. Oral Oncol 48: 393-398, 2012
6. Paissat DK: Oral submucous fibrosis. Int J Oral Surg 10: 307-312, 1981
7. Aziz SR: Oral submucous fibrosis: An unusual disease. J N J Dent Assoc 68: 17-19, 1997
8. Warnakulasuriya S, Johnson NW and van der Waal I: Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36: 575-580, 2007
9. Tilakaratne WM, Klinikowski MF, Saku T, et al: Oral submucous fibrosis: Review on aetiology and pathogenesis. Oral Oncol 42: 561-568, 2006
10. Walvekar RR, Chaukar DA, Deshpande MS, et al: Verrucous carcinoma of the oral cavity: A clinical and pathological study of 101 cases. Oral Oncol 45: 47-51, 2009
11. Thomas SJ, Bain CJ, Battistutta D, et al: Betel quid not containing tobacco and oral cancer: A report on a case-control study in Papua New Guinea and a meta-analysis of current evidence. Int J Cancer 120: 1318-1323, 2007
12. Ko YC, Huang YL, Lee CH, et al: Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 24: 450-453, 1995
13. Panigrahi GB and Rao AR: Chromosome-breaking ability of arecoline, a major betel-nut alkaloid, in mouse bone-marrow cells in vivo. Mutat Res 103: 197-204, 1982
14. Chou WW, Guh JY, Tsai JF, et al: Arecoline-induced phosphorylated p53 and p21(WAF1) protein expression is dependent on ATM/ATR and phosphatidylinositol-3-kinase in clone-9 cells. J Cell Biochem 107: 408-417, 2009
15. Stich HF, Stich W and Lam PP: Potentiation of genotoxicity by concurrent application of compounds found in betel quid: Arecoline, eugenol, quercetin, chlorogenic acid and Mn2+. Mutat Res 90: 355-363, 1981
16. Jeng JH, Chang MC and Hahn LJ: Role of areca nut in betel quid-associated chemical carcinogenesis: Current awareness and future perspectives. Oral Oncol 37: 477-492, 2001
17. Dasgupta R, Saha I, Pal S, et al: Immunosuppression, hepatotoxicity and depression of antioxidant status by arecoline in albino mice. Toxicology 227: 94-104, 2006
18. Grutter MG: Caspases: Key players in programmed cell death. Curr Opin Struct Biol 10: 649-655, 2000
19. Crowder RN and El-Deiry WS: Caspase-8 regulation of TRAIL-mediated cell death. Exp Oncol 34: 160-164, 2012
20. Cory S and Adams JM: The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002
21. Ghiotto F, Fais F and Bruno S: BH3-only proteins: The death-puppeteer's wires. Cytometry A 77: 11-21, 2010
22. Tait SW and Green DR: Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11: 621-632, 2010
23. Kantari C and Walczak H: Caspase-8 and bid: Caught in the act between death receptors and mitochondria. Biochim Biophys Acta 1813: 558-563, 2011
24. Wang K, Yin XM, Chao DT, et al: BID: A novel BH3 domain-only death agonist. Genes Dev 10: 2859-2869, 1996
25. Li H, Zhu H, Xu CJ, et al: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998
26. Luo X, Budihardjo I, Zou H, et al: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998
27. Gross A, Yin XM, Wang K, et al: Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274: 1156-1163, 1999
28. Reichart PA: Oral cancer and precancer related to betel and miang chewing in Thailand: A review. J Oral Pathol Med 24: 241-243, 1995
29. Trivedy CR, Craig G and Warnakulasuriya S: The oral health consequences of chewing areca nut. Addict Biol 7: 115-125, 2002
30. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum 85: 1-334, 2004
31. Chang MC, Lin LD, Wu HL, et al: Areca nut-induced buccal mucosa fibroblast contraction and its signaling: A potential role in oral submucous fibrosis - a precancer condition. Carcinogenesis 34: 1096-1104, 2013
32. Li X, Ling TY, Gao YJ, Tang, DS, Li WH: Arecoline and oral keratinocytes may affect the collagen metabolism of fibroblasts. J Oral Pathol Med 38: 422-426, 2009
33. Yang SF, Hsieh YS, Tsai CH, et al: Increased plasminogen activator inhibitor-1/tissue type plasminogen activator ratio in oral submucous fibrosis. Oral Dis 13: 234-238, 2007
34. Chiang SL, Chen PH, Lee CH, et al: Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2 -1195G>a polymorphism reveal risk of oral cancer. Cancer Res 68: 8489-8498, 2008
35. Shieh DH, Chiang LC and Shieh TY: Augmented mRNA expression of tissue inhibitor of metalloproteinase-1 in buccal mucosal fibroblasts by arecoline and safrole as a possible pathogenesis for oral submucous fibrosis. Oral Oncol 39: 728-735, 2003
36. Shieh DH, Chiang LC, Lee CH, et al: Effects of arecoline, safrole, and nicotine on collagen phagocytosis by human buccal mucosal fibroblasts as a possible mechanism for oral submucous fibrosis in Taiwan. J Oral Pathol Med 33: 581-587, 2004
37. Khan I, Kumar N, Pant I, et al: Activation of TGF-beta pathway by areca nut constituents: A possible cause of oral submucous fibrosis. PloS One 7: E51806, 2012
38. Kale AD, Mane DR and Shukla D: Expression of transforming growth factor beta and its correlation with lipodystrophy in oral submucous fibrosis: An immunohistochemical study. Med Oral Patol Oral Cir Bucal 18: E12-e18, 2013
39. Yu CC, Tsai CH, Hsu HI, et al: Elevation of S100A4 expression in buccal mucosal fibroblasts by arecoline: Involvement in the pathogenesis of oral submucous fibrosis. PloS One 8: E55122, 2013
40. Deng YT, Chen HM, Cheng SJ, et al: Arecoline-stimulated connective tissue growth factor production in human buccal mucosal fibroblasts: Modulation by curcumin. Oral Oncol 45: E99-e105, 2009
41. Nair J, Ohshima H, Friesen M, et al: Tobacco-specific and betel nut-specific N-nitroso compounds: Occurrence in saliva and urine of betel quid chewers and formation in vitro by nitrosation of betel quid. Carcinogenesis 6: 295-303, 1985
42. Shirname LP, Menon MM, Nair J, et al: Correlation of mutagenicity and tumorigenicity of betel quid and its ingredients. Nutr Cancer 5: 87-91, 1983
43. Cox S, Vickers ER, Ghu S and Zoellner H: Salivary arecoline levels during areca nut chewing in human volunteers. J Oral Pathol Med 39: 465-469, 2010
44. Sundqvist K, Liu Y, Nair J, et al: Cytotoxic and genotoxic effects of areca nut-related compounds in cultured human buccal epithelial cells. Cancer Res 49: 5294-5298, 1989
45. Lee PH, Chang MC, Chang WH, et al: Prolonged exposure to arecoline arrested human KB epithelial cell growth: Regulatory mechanisms of cell cycle and apoptosis. Toxicology 220: 81-89, 2006
46. Tseng SK, Chang MC, Su CY, et al: Arecoline induced cell cycle arrest, apoptosis, and cytotoxicity to human endothelial cells. Clin Oral Investig 16: 1267-1273, 2012
47. Zhou ZS, Li M, Gao F, et al: Arecoline suppresses HaCaT cell proliferation through cell cycle regulatory molecules. Oncol Rep 29: 2438-2444, 2013
48. Shih YT, Chen PS, Wu CH, et al: Arecoline, a major alkaloid of the areca nut, causes neurotoxicity through enhancement of oxidative stress and suppression of the antioxidant protective system. Free Radic Biol Med 49: 1471-1479, 2010
49. Cheng HL, Su SJ, Huang LW, et al: Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis - involvement of STAT3 and RhoA activation. Mol Cancer 9: 126, 2010